https://nova.newcastle.edu.au/vital/access/manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:41994 Wed 30 Aug 2023 15:43:30 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:53474 Wed 28 Feb 2024 15:13:50 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:50696 Wed 28 Feb 2024 15:12:52 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:47703 Wed 25 Jan 2023 10:34:30 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:36899 Wed 24 Nov 2021 15:53:26 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:51394 Wed 24 Apr 2024 12:04:11 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:36902 Wed 23 Feb 2022 16:03:35 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:51823 .80) were good for both PROMIS measures and comparable to or better than all legacy measures. At the recommended mild cut-point (55), PROMIS-A-SF had sensitivity (.67) comparable to or better than all the legacy measures, whereas PROMIS-A-CAT sensitivity (.59) was lower than GAD-7 (.67) and HADS-A (.62), but comparable to PSYCH-6 and higher than DASS-A, DASS-S and DT. Sensitivity for both was.79. A reduced cut-point of 51 on both PROMIS measures improved sensitivity (.83–.84) although specificity was only adequate (.61–.62). Conclusions: The convergent and criterion validity of the PROMIS anxiety measures in cancer populations was confirmed as equivalent, but not superior to, established measures (GAD-7 and HADS-A). The PROMIS-A-CAT did not demonstrate clear advantages over PROMIS-A-SF.]]> Wed 20 Sep 2023 10:14:01 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:54898 Wed 20 Mar 2024 13:32:26 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:48925 Wed 19 Apr 2023 15:49:30 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:53433 120 mmHg) in the PMBE group reduced by − 6.46 mmHg (p = 0.001) at 12 weeks compared to baseline. No significant changes were reported for individuals with optimal (≤120 mmHg) SBP nor did DBP significantly change in either study groups. In individuals with non-medicated normal-high SBP, SBP significantly reduced by − 7.49 mmHg (p = 0.001) and DBP by − 3.06 mmHg (p = 0.011) at 12 weeks compared to baseline after PMBE. Cross-group comparisons were not statistically different. Conclusions: A polyphenol-rich dietary supplement derived from PMBE led to a clinically and statistically significant reduction in SBP in adults. Future studies to investigate the effects of PMBE-polyphenol supplementation on BP are warranted to confirm and explore optimal dose and impact on hypertension.]]> Wed 17 Apr 2024 14:49:50 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:47145 Wed 14 Dec 2022 15:27:34 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:47086 0.05). Similar results were found for IBS subtypes. Higher serum L-arginine concentration had the strongest association with IBS diagnosis, with an odds ratio of 9.03 for those with serum L-arginine at the 75th (84 μmol/L) versus 25th (46 μmol/L) percentile (95% CI: 5.99–13.62). L-arginine had the best discriminative ability with a bias-adjusted area under the receiver operator characteristic curve of 0.859. Conclusions: Higher serum concentrations of L-arginine and endogenous methylarginines are strongly associated with IBS in adults.]]> Wed 14 Dec 2022 09:23:38 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:47342 Wed 13 Mar 2024 07:50:16 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:50277 90% of clinicians would continue specialist follow-up for at least 5 years. The majority of clinicians felt that patients experienced disproportionate fear of recurrence and were reassured by follow-up. After multivariable analysis, clinicians who participated in multidisciplinary teams (MDTs) were more likely to choose de-escalated care for both initial treatment (p = .005) and follow-up care (>5 years, p = .05). Conclusion: Clinician attitudes captured by this survey reflect recent changes in guidelines towards hemithyroidectomy for low-risk WDTC, particularly amongst MDT attendees. There is a need to further examine the impact of de-escalated care on fear of recurrence and quality of life in thyroid cancer survivors.]]> Wed 12 Jul 2023 16:24:11 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:36123 Wed 12 Feb 2020 15:26:21 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:35488 Wed 10 Nov 2021 15:13:44 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:37857 Wed 10 Nov 2021 15:12:46 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:46031 NTR), are increasingly implicated in cancer progression, but their clinicopathological significance in oesophageal cancer is unclear. In this study, the expression of NGF, NTRK1 and NGFR were analysed by immunohistochemistry in a cohort of 303 oesophageal cancers versus 137 normal adjacent oesophageal tissues. Immunostaining was digitally quantified and compared to clinicopathological parameters. NGF and NGFR staining were found in epithelial cells and at similar levels between oesophageal cancers and normal oesophageal tissue. NGFR staining was slightly increased with grade (p=0.0389). Interestingly, NTRK1 staining was markedly higher in oesophageal squamous cell carcinoma (OR 2.31, 95%CI 1.13–4.38, p<0.0001) and significantly lower in adenocarcinoma (OR 0.50, 95%CI 0.44–0.63, p<0.0001) compared to normal oesophageal tissue. In addition, NTRK1 staining was decreased in grade 2 and grade 3 (OR 0.51, 95%CI 0.21–1.40, p<0.0001) compared to grade 1, suggesting a preferential involvement of this receptor in the more differentiated forms of oesophageal carcinomas. Together, these data point to NTRK1 as a biomarker and a candidate therapeutic target in oesophageal squamous cell carcinoma.]]> Wed 09 Nov 2022 15:59:02 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:36882 Wed 07 Apr 2021 20:17:02 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:43981 Wed 05 Oct 2022 14:29:29 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:43939 Wed 05 Oct 2022 12:51:37 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:48036 Wed 05 Jul 2023 15:42:32 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:49019 Wed 03 May 2023 12:31:33 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:52879 Tue 31 Oct 2023 10:46:40 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:52882 Tue 31 Oct 2023 10:45:23 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:49758 Tue 30 May 2023 18:03:39 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:54057 Tue 30 Jan 2024 13:56:43 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:46724 Tue 29 Nov 2022 11:27:33 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:41826 Tue 28 Mar 2023 11:27:44 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:41416 Tue 28 Feb 2023 10:18:59 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:52010 Tue 26 Sep 2023 11:37:17 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:39823 Tue 26 Jul 2022 13:52:10 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:31136 Tue 24 Mar 2020 13:00:17 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:38855 Tue 22 Feb 2022 15:26:26 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:44624 P<.0001; with adjustment for infant sex and maternal body mass index). Indigenous mean birthweight percentile was 4.2 units lower (P<.0001). Adjustment for maternal age, smoking, body mass index, and infant sex reduced the difference in birthweight/percentiles to nonsignificance (12 g; P=.07). Conclusion: Disparities exist between indigenous and non-indigenous Australian infants for birthweight, birthweight percentile, and adverse outcome rates. Adjustment for smoking and maternal age removed any significant difference in birthweights and birthweight percentiles for indigenous infants. Our data indicate that birthweight percentiles should not be adjusted for indigenous ethnicity because this normalizes disadvantage; because White and indigenous Australians have diverged for approximately 50,000 years, it is likely that the same conclusions apply to other ethnic groups. The disparities in birthweight percentiles that are associated with smoking will likely perpetuate indigenous disadvantage into the future because low birthweight is linked to the development of chronic noncommunicable disease and poorer educational attainment; similar problems may affect other indigenous populations.]]> Tue 18 Oct 2022 11:09:49 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:46351 n = 115) and Perth (n = 30), Australia. The Newcastle cohort was enriched with people with asthma (n = 37) and COPD (n = 38). Gene expression for ACE2 and other genes potentially associated with SARS-CoV-2 cell entry was assessed by qPCR, and protein expression was confirmed with immunohistochemistry on endobronchial biopsies and cultured AEC. Results: Increased gene expression of ACE2 was associated with older age (P = 0.03) and male sex (P = 0.03), but not with pack-years smoked. When we compared gene expression between adults with asthma, COPD and healthy controls, mean ACE2 expression was lower in asthma patients (P = 0.01). Gene expression of furin, a protease that facilitates viral endocytosis, was also lower in patients with asthma (P = 0.02), while ADAM-17, a disintegrin that cleaves ACE2 from the surface, was increased (P = 0.02). ACE2 protein expression was also reduced in endobronchial biopsies from asthma patients. Conclusion: Increased ACE2 expression occurs in older people and males. Asthma patients have reduced expression. Altered ACE2 expression in the lower airway may be an important factor in virus tropism and may in part explain susceptibility factors and why asthma patients are not over-represented in those with COVID-19 complications.]]> Tue 15 Nov 2022 15:15:58 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:42696 Tue 14 Nov 2023 14:44:08 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:48285 Tue 14 Mar 2023 10:57:37 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:47057 Tue 13 Dec 2022 15:32:32 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:38509 Tue 12 Oct 2021 15:53:00 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:52391 Tue 10 Oct 2023 14:47:07 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:39116 Tue 10 May 2022 15:01:34 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:50517 Tue 08 Aug 2023 14:23:37 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:37736 Tue 08 Aug 2023 10:33:20 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:42275 Tue 07 Nov 2023 11:20:11 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:54123 Tue 06 Feb 2024 11:21:33 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:43825 Tue 04 Oct 2022 11:04:55 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:45371 Thu 27 Oct 2022 15:11:36 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:44843 Thu 27 Oct 2022 12:38:47 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:45304 Thu 27 Oct 2022 09:40:15 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:37872 Thu 27 May 2021 15:52:03 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:45682 Thu 25 Jan 2024 14:40:06 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:46513 Thu 24 Nov 2022 15:43:28 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:37693 Thu 24 Mar 2022 11:33:04 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:37496 N = 132. The 19-item survey questioned the likelihood that the participant would use the various supports for their health, to quit smoking, and for a baby or child’s health. Logistic regression analyses were performed on N = 98 with complete data. Older participants were less likely to use Facebook or the internet for their health, or the health of a child, but were more likely to consult with health professionals. Women who had quit smoking were less likely to use an app for their health compared to smokers. Women who had a child living in their household were less likely to use the internet for a child’s health. This community-based study revealed age-related differences for access to health services and differences according to smoking status. Patterns of internet and app use warrant further consideration when planning strategies to improve Aboriginal and Torres Strait Islander women and children’s health.]]> Thu 21 Jan 2021 15:05:20 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:39156 2 (1, n = 19; 19.0, p = 0.392)). Inter-rater agreement for the modified 81-item Home-CookERI™ was almost-perfect to perfect for 46% of kitchen items (n = 37 items, κ = 0.81–1), moderate to substantial for 28% (n = 23, κ = 0.51–0.8), slight to fair for 15% (n = 12, κ = 0.01–0.5), and chance or worse for 11% of items (n = 9, κ ≤ 0.0). Home-CookERITM was further optimized by reduction to a 77-item version, which is now available to researchers. Conclusion: Home-CookERI™ is a comprehensive tool for quantifying Australian household cooking environments. It has excellent face and content validity and moderate to perfect inter-rater agreement for almost three-quarters of included kitchen items. To expand Home-CookERI™ applications, a home occupant self-completion version is planned for validation.]]> Thu 19 May 2022 16:29:44 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:37954 Thu 16 Nov 2023 12:21:57 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:38922 Thu 16 Nov 2023 12:20:26 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:48866 Thu 13 Apr 2023 10:01:04 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:49322 Thu 11 May 2023 15:00:33 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:39920 Thu 11 Aug 2022 14:36:04 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:45421 Thu 10 Nov 2022 10:30:53 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:38626 Thu 09 Dec 2021 14:48:14 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:52248 Thu 05 Oct 2023 14:00:13 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:52228 Thu 05 Oct 2023 10:31:13 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:38633 Thu 02 Dec 2021 15:37:24 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:46836 Thu 01 Dec 2022 15:01:24 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:49208 Sun 07 May 2023 09:30:14 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:50640 Mon 31 Jul 2023 16:34:24 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:37590 Mon 29 Mar 2021 10:17:19 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:38996 n 5324), without CVD, hypertension and diabetes at baseline (2001), with complete FFQ data. Results: There were 1342 new cases of hypertension and 629 new cases of non-fatal CVD over 15 years of follow-up. Multivariate analysis indicated that women reporting better adherence to the ARFS (≥38/74) had 15 % (95 % CI 1, 28 %; P = 0·05) lower odds of hypertension and 46 % (95 % CI 6, 66 %; P = 0·1) lower odds of non-fatal CVD. Women reporting better adherence to the MDS (≥8/17) had 27 % (95 % CI 15, 47 %; P = 0·0006) lower odds of hypertension and 30 % (95 % CI 2, 50 %; P = 0·03) lower odds of non-fatal CVD. Conclusions: Better adherence to diet quality scores is associated with lower risk of hypertension and non-fatal CVD. These results support the need for updated evidenced based on the ADG as well as public health nutrition policies in Australia.]]> Mon 29 Jan 2024 17:54:29 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:44809 2 times/week but 1 but ≤2 times/week (6·8 kg (95 % CI 1·8, 11·8); 2·1 kg/m2 (95 % CI 0·3, 4·0) and 6·0 cm (95 % CI 1·7, 10·4)). This association was dose-dependent such that for every increase in category of weekly meat intake (i.e. >1 time/week but ≤2 times/week; >2 times/week but less than daily, and daily or multiple times/d), an associated 2·6 kg (95 % CI 1·8, 3·4) increase in BW, 0·9 kg/m2 (95 % CI 0·6, 1·2) increase in BMI and 2·3 cm (95 % CI 1·6, 3·0) increase in WC was reported. Conclusions: BW, BMI and WC are lower in women following PBD and positively associated with increasing meat consumption. Results were robust to adjustment for confounders including physical activity levels, smoking status, habitual alcohol intake, use of supplements, and hormone replacement therapy.]]> Mon 24 Oct 2022 09:31:34 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:44738 Mon 24 Oct 2022 08:35:40 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:37649 Mon 23 Aug 2021 12:41:17 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:49544 Mon 22 May 2023 08:45:35 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:49545 Mon 22 May 2023 08:45:20 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:39754 Mon 20 Jun 2022 12:01:11 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:46239 Mon 14 Nov 2022 13:07:50 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:50955 Mon 14 Aug 2023 14:36:36 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:54187 Mon 12 Feb 2024 13:54:25 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:46970 Mon 12 Dec 2022 16:19:30 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:54761 Mon 11 Mar 2024 15:00:58 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:41992 Mon 10 Jul 2023 11:24:21 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:55063 65%) of students. Most students (mean age = 17) did not know that early sexual debut (before 18 years) is a risk factor for cervical cancer (72%) and that a blood test cannot detect cervical cancer (71%). Students in later stages of senior high school education and those who received sexual health education from teachers and parents had significantly greater cervical cancer knowledge scores than their counterparts. Interactive effects showed that school-based sexual health education was associated with higher knowledge scores than home-based education among students. Conclusions: Most female senior high school students had gaps in knowledge about cervical cancer prevention. Finding new ways to strengthen the capacity of schools and parents to deliver accurate cervical cancer prevention information is warranted.]]> Mon 08 Apr 2024 12:39:07 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:36898 Fri 21 Jan 2022 09:24:17 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:49503 Fri 19 May 2023 12:58:08 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:42290 Fri 19 Aug 2022 14:58:36 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:50835 Fri 18 Aug 2023 10:27:30 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:39651 Fri 17 Jun 2022 13:19:10 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:44472 Fri 14 Oct 2022 08:43:40 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:49424 Fri 12 May 2023 15:09:21 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:49387 60 years old and accepted onto the National Organ Matching Service. This RKT Group was divided into donor renal cancers ≤30 mm and >30–≤50 mm. Adverse event profiles for RKT recipients were compared with 22 standard live donor recipients using logistic regression analyses. Recipient and transplant survivals for RKT were compared with 2050 controls from Australian New Zealand Dialysis Transplant Registry using Cox regression models. To increase statistical power for survival analyses, data from 25 RKT recipients from Princess Alexandra Hospital, Brisbane were added, thus creating 48 RKT recipients.Results: There were no significant differences in mortality, transplant failure nor AEs between the 2 cancer Groups. RKT increased the risks of Adverse event profiles (odds ratio: 6.48 [2.92–15.44]; P < 0.001). RKT reduced mortality risk by 30% (hazard ratio [HR]: 0.70 [0.36–1.07]; P = 0.299) compared with those continuing on the transplant list who may or may not be transplanted. RKT significantly reduced mortality risk for those remaining on dialysis (HR: 2.86 [1.43–5.72]; P = 0.003). Transplant survival for RKT was reduced compared with control deceased donor (HR: 0.42 [0.21–0.83]; P = 0.013) and live donor transplants (HR: 0.33 [0.02–0.86]; P =0.023).Conclusions:The use of larger carefully selected cancer-resected kidneys for transplantation appears safe and effective. RKT confers a possible survival advantage compared with waiting for transplantation, an increased survival compared with those remaining on dialysis but reduced transplant survival.]]> Fri 12 May 2023 14:27:13 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:49366 Fri 12 May 2023 12:42:14 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:38429 p = 0.04, ROC AUC 0.90) and standard deviation (SD) (p = 0.02, ROC AUC 0.90), week 2 skewness (p = 0.02, ROC AUC 0.91) and SD (p = 0.01, ROC AUC 0.94), week 4 kurtosis (p = 0.01, AUC 0.92) and SD (p = 0.01, ROC AUC 0.96). Changes in minimum ADC between baseline and week 2 (p = 0.02, ROC AUC 0.94) and baseline and week 4 (p = 0.02, ROC AUC 0.94) were prognostic for local recurrence. For prediction of any recurrence, ADC minimum (p = 0.02, ROC AUC 0.87) and SD (p = 0.01, ROC AUC 0.85) at baseline, and ADC maximum (p = 0.03, ROC AUC 0.77) and SD (p = 0.02, ROC AUC 0.81) at week 4 were significant. On LASSO logistic regression, ADC minimum and SD at baseline were retained for any recurrence. The only significant finding for DCE-MRI was a correlation of k-trans min at the second follow-up with local recurrence (p = 0.05, AUC 0.84). Conclusion: Several ADC parameters at various time points correlate with recurrence suggesting DW-MRI is a potential biomarker for SCCAC.]]> Fri 10 Sep 2021 12:16:47 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:38253 Fri 03 Sep 2021 14:46:19 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:51357 Fri 01 Sep 2023 13:45:52 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:51363 Fri 01 Sep 2023 13:43:43 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:51351 Fri 01 Sep 2023 13:36:25 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:39989 N = 378 participated. Response rates 8.4% (N = 42; online survey) and 6% (N = 335; paper survey), respectively. Total percentages agreeing with system-based changes: 79% training, 64% oral NRT subsidy, 62% Medicare item for smoking cessation, 54% improved access to NRT patches. Within RANZCOG, more GPs (73.1%) agreed that oral NRT should be subsidised (P = 0.001) than obstetricians (53.7%). Conclusion: GPs and obstetricians agreed that system changes would improve their management of smoking in pregnancy. Oral NRT subsidy was the only pairwise group difference. Subsequently, oral NRT has been subsidised; in time, this may influence prescribing and quit rates.]]> Fri 01 Jul 2022 13:00:40 AEST ]]>